Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|August 10, 2020
RA Quiz: How often should RA patients be screened for CVD?
Author(s)Ingrid Torjesen
Patients with rheumatoid arthritis have an increased risk of cardiovascular events and cardiovascular death. How much do you know about cardiovascular risk related to rheumatoid arthritis and its treatment?
Advertisement
By how much is rheumatoid arthritis believed to increase the risk of cardiovascular disease?
- 1 to 1.5 fold
- 1.5 to 2 fold
- 2 to 2.5 fold
- 2.5 to 3 fold
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement